Ajanta Pharma Limited — Q4 FY24
Ajanta Pharma delivered a strong Q4 FY24 with revenue of INR 1,054 crore (+20% YoY), EBITDA of INR 278 crore (+86% YoY), and PAT of INR 203 crore (+66% YoY).
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY24
FY24 EBITDA margin guidance revised to 27% ±1%
Management revised full-year EBITDA margin guidance to 27% ±1%, down from 28% in 9M, due to higher freight costs from Red Sea crisis and increased Q4 expenses.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1
Q3 FY24
India business to grow low double digits in FY24
India business expected to grow 12-13% for full year FY24, with Q4 aspiration to cross 15%.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1
Q3 FY24
Asia branded to grow low teens in FY24
Asia branded business expected to grow low double digits for full year FY24.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1
Q3 FY24
Africa branded to grow mid to high single digits in FY24
Africa branded business expected to grow mid to high single digits for full year FY24.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1